The global inflammatory bowel disease treatment market size is expected to reach USD 22.4 billion by 2026, according to a new report by Grand View Research, Inc., registering a 4.4% CAGR during the forecast period. Increasing prevalence and incidence of Crohn’s disease and ulcerative colitis is one of the major factors contributing to the market.
According to a study published in the NCBI in 2019, the North America incidence of inflammatory bowel disease (IBD) treatment is around 2.2 to 19.2 cases per 100,000 persons per year. It was also published that around 238 per 100,000 population in U.S. were suffering from ulcerative colitis. Furthermore, The Centers for Disease Control and Prevention (CDC) estimates that in U.S., every year nearly 1-1.3 million people suffer from inflammatory bowel disease.
In addition, involvement of regulatory bodies for funding and designation is expected to propel the growth of the market. For instance, the Crohn’s and Colitis Foundation offers grants and fellowships for research on inflammatory bowel disease (includes Crohn’s disease and ulcerative colitis).
Growing geriatric population is expected to positively impact the overall market. According to an article published in 2018 in the United States Census Bureau, it is estimated that by 2035, the population aged 65 years and above is expected to reach 78 million, whereas children under the age of 18 might be around 76.7million.
Moreover, companies such as Johnson & Johnson Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; and AbbVie Inc. are majorly involved in product research and development and this is also considered as one of the major driving factors for the market.
To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market
Further key findings from the report suggest:
-
The global inflammatory bowel disease treatment market is anticipated to reach USD 22.4 billion by 2026, exhibiting a CAGR of 4.4% from 2018 to 2026
-
Crohn’s disease dominated the market by type in 2018 due to increasing incidence of the disease. On the other hand, ulcerative colitis was estimated to be the fastest growing segment owing to presence of strong pipeline products for its treatment
-
By route of administration, injectables dominated the IBD treatment market in 2018 while oral was estimated to be the fastest growing segment over the forecast period
-
Aminosalicylic acid (ASAs) was considered to be the largest oral segment in 2018 and JAK inhibitors to be the fastest growing segment
-
In 2018, TNF-inhibitors dominated the injectables segment while anti-integrins are estimated to be the fastest growing segment
-
Hospital pharmacy was the largest segment in 2018 with a market share of 36.6% and online pharmacy was anticipated to be the fastest owing to the comfort, flexibility and convenience provided
-
North America held the dominant share in 2018 owing to presence of key companies in this region. Asia Pacific, on the other hand, was estimated to be the fastest growing region
-
Some of the key companies operating in this market are Johnson & Johnson Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Celltrion Healthcare Co., Ltd.; CELGENE CORPORATION; COSMO PHARMACEUTICALS; Innovate Biopharmaceuticals; UCB S.A.; and Gilead Sciences.
Grand View Research has segmented the global inflammatory bowel disease treatment market based on type, route of administration, distribution channel, and region:
IBD Treatment Type Form Outlook (Revenue, USD Million, 2014 – 2026
-
Crohn’s disease
-
Ulcerative colitis
IBD Treatment Route of Administration Outlook (Revenue, USD Million, 2014 – 2026)
-
Injectables
-
TNF-inhibitors
-
IL inhibitors
-
Anti-integrin
-
Others
-
-
Oral
-
ASAs
-
Corticosteroids
-
JAK inhibitors
-
Others
-
IBD Treatment Distribution Channel Outlook (Revenue, USD Million, 2014 – 2026)
-
Hospital Pharmacy
-
Retail Pharmacy
-
Online Pharmacy
IBD Treatment Regional Outlook (Revenue, USD Million, 2014 – 2026)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
U.K.
-
Germany
-
France
-
Italy
-
Spain
-
-
Asia Pacific
-
Japan
-
China
-
India
-
South Korea
-
Australia
-
Singapore
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
UAE
-
Saudi Arabia
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market